Drugs / 3,4-methylenedioxymethamphetamine (MDMA)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05584826 | Oct 2022 → Oct 2026 expected | adjustment disorder, cancer | Sunstone Medical | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3,4-methylenedioxymethamphetamine (MDMA) | “3,4-methylenedioxymethamphetamine (MDMA)” NCT05584826 ↗ |
| Known as | MDMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05584826 ↗ |